Literature DB >> 23166342

Predictors of persistence after a positive depression screen among adolescents.

Laura P Richardson1, Elizabeth McCauley, Carolyn A McCarty, David C Grossman, Mon Myaing, Chuan Zhou, Julie Richards, Carol Rockhill, Wayne Katon.   

Abstract

OBJECTIVE: To examine predictors of depression persistence after a positive screening test to inform management protocols for screened youth.
METHODS: We conducted a cohort study of 444 youth (aged 13-17 years) from a large health care delivery system. Youth with depressive symptoms, based on a 2-item depression screen, were oversampled for the baseline interview. Baseline assessments included the Patient Health Questionnaire 9-item (PHQ-9) depression screen as well as clinical factors that were hypothesized to influence depression persistence (family history of depression, functional impairment, perceived social support, anxiety symptoms, externalizing symptoms, and medical comorbidity). Logistic regression analysis was used to examine factors associated with the persistence of depression at 6 months postbaseline.
RESULTS: Of 113 youth with a positive baseline screen (PHQ-9 ≥11), 47% and 35% continued to be positive at 6-week and 6-month follow-up, respectively. After controlling for treatment status, only 2 factors were significantly associated with depression persistence at 6 months: baseline depressive symptom score and continuing to have a positive screen at 6 weeks. For each 1-point increase on the PHQ-9 score at baseline, youth had a 16% increased odds of continuing to be depressed at 6 months (odds ratio: 1.16, 95% confidence interval: 1.01-1.34). Youth who continued to screen positive 6 weeks later had almost 3 times the odds of being depressed at 6 months (odds ratio: 2.89, 95% confidence interval: 1.09-7.61).
CONCLUSIONS: Depressive symptom severity at presentation and continued symptoms at 6 weeks postscreening are the strongest predictors of depression persistence. Patients with high depressive symptom scores and continued symptoms at 6 weeks should receive active treatment.

Entities:  

Mesh:

Year:  2012        PMID: 23166342      PMCID: PMC3507250          DOI: 10.1542/peds.2012-0450

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  30 in total

1.  Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial.

Authors:  M B Keller; N D Ryan; M Strober; R G Klein; S P Kutcher; B Birmaher; O R Hagino; H Koplewicz; G A Carlson; G N Clarke; G J Emslie; D Feinberg; B Geller; V Kusumakar; G Papatheodorou; W H Sack; M Sweeney; K D Wagner; E B Weller; N C Winters; R Oakes; J P McCafferty
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-07       Impact factor: 8.829

2.  Evaluation of the Patient Health Questionnaire-9 Item for detecting major depression among adolescents.

Authors:  Laura P Richardson; Elizabeth McCauley; David C Grossman; Carolyn A McCarty; Julie Richards; Joan E Russo; Carol Rockhill; Wayne Katon
Journal:  Pediatrics       Date:  2010-11-01       Impact factor: 7.124

3.  A randomized trial of relapse prevention of depression in primary care.

Authors:  W Katon; C Rutter; E J Ludman; M Von Korff; E Lin; G Simon; T Bush; E Walker; J Unützer
Journal:  Arch Gen Psychiatry       Date:  2001-03

4.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

5.  Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database.

Authors:  Arif Khan; Robyn M Leventhal; Shirin R Khan; Walter A Brown
Journal:  J Clin Psychopharmacol       Date:  2002-02       Impact factor: 3.153

6.  Long-term prognosis of depression in primary care.

Authors:  G E Simon
Journal:  Bull World Health Organ       Date:  2000       Impact factor: 9.408

7.  Validity of brief alcohol screening tests among adolescents: a comparison of the AUDIT, POSIT, CAGE, and CRAFFT.

Authors:  John R Knight; Lon Sherritt; Sion Kim Harris; Elizabeth C Gates; Grace Chang
Journal:  Alcohol Clin Exp Res       Date:  2003-01       Impact factor: 3.455

8.  Quality of care for medicaid-covered youth treated with antidepressant therapy.

Authors:  Laura P Richardson; David DiGiuseppe; Dimitri A Christakis; Elizabeth McCauley; Wayne Katon
Journal:  Arch Gen Psychiatry       Date:  2004-05

9.  Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial.

Authors:  Graham J Emslie; John H Heiligenstein; Karen Dineen Wagner; Sharon L Hoog; Daniel E Ernest; Eileen Brown; Mary Nilsson; Jennie G Jacobson
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-10       Impact factor: 8.829

Review 10.  Epidemiology of depression in primary care.

Authors:  W Katon; H Schulberg
Journal:  Gen Hosp Psychiatry       Date:  1992-07       Impact factor: 3.238

View more
  13 in total

1.  Twelve-Month Outcomes of a Randomized Trial of the Positive Thoughts and Action Program for Depression Among Early Adolescents.

Authors:  Mylien T Duong; Rick A Cruz; Kevin M King; Heather D Violette; Carolyn A McCarty
Journal:  Prev Sci       Date:  2016-04

2.  Determinants of mental health service use among depressed adolescents.

Authors:  David J Breland; Carolyn A McCarty; Chuan Zhou; Elizabeth McCauley; Carol Rockhill; Wayne Katon; Laura P Richardson
Journal:  Gen Hosp Psychiatry       Date:  2013-12-10       Impact factor: 3.238

3.  Mediators and Moderators of a School-Based Cognitive-Behavioral Depression Prevention Program.

Authors:  Mylien T Duong; Brynn M Kelly; Wren L Haaland; Brandon Matsumiya; Stanley J Huey; Carolyn A McCarty
Journal:  Cognit Ther Res       Date:  2016-04-28

4.  Collaborative Care for Adolescents With Persistent Postconcussive Symptoms: A Randomized Trial.

Authors:  Carolyn A McCarty; Douglas Zatzick; Elizabeth Stein; Jin Wang; Robert Hilt; Frederick P Rivara
Journal:  Pediatrics       Date:  2016-09-13       Impact factor: 7.124

5.  A randomized trial of the Positive Thoughts and Action program for depression among early adolescents.

Authors:  Carolyn A McCarty; Heather D Violette; Mylien T Duong; Rick A Cruz; Elizabeth McCauley
Journal:  J Clin Child Adolesc Psychol       Date:  2013-04-05

6.  Usual Care for Adolescent Depression From Symptom Identification Through Treatment Initiation.

Authors:  Briannon C O'Connor; R Eric Lewandowski; Stephanie Rodriguez; Aldo Tinoco; William Gardner; Kimberly Hoagwood; Sarah Hudson Scholle
Journal:  JAMA Pediatr       Date:  2016-04       Impact factor: 16.193

7.  Initial Findings from a Novel School-Based Program, EMPATHY, Which May Help Reduce Depression and Suicidality in Youth.

Authors:  Peter H Silverstone; Marni Bercov; Victoria Y M Suen; Andrea Allen; Ivor Cribben; Jodi Goodrick; Stu Henry; Catherine Pryce; Pieter Langstraat; Katherine Rittenbach; Samprita Chakraborty; Rutger C Engels; Christopher McCabe
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

8.  The effectiveness and cost-effectiveness of a mindfulness training programme in schools compared with normal school provision (MYRIAD): study protocol for a randomised controlled trial.

Authors:  Willem Kuyken; Elizabeth Nuthall; Sarah Byford; Catherine Crane; Tim Dalgleish; Tamsin Ford; Mark T Greenberg; Obioha C Ukoumunne; Russell M Viner; J Mark G Williams
Journal:  Trials       Date:  2017-04-26       Impact factor: 2.279

9.  Barriers and facilitators for mental healthcare in pediatric lupus and mixed connective tissue disease: a qualitative study of youth and parent perspectives.

Authors:  Andrea M Knight; Michelle E Vickery; Alexander G Fiks; Frances K Barg
Journal:  Pediatr Rheumatol Online J       Date:  2015-11-24       Impact factor: 3.054

Review 10.  Health risk behavior among chronically ill adolescents: a systematic review of assessment tools.

Authors:  Derrick Ssewanyana; Moses Kachama Nyongesa; Anneloes van Baar; Charles R Newton; Amina Abubakar
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2017-07-17       Impact factor: 3.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.